SEQUA Share Price Performance
€1.38
0.38 (37.60%)
Price €1.38
Share Price€1.38
SEQUA Community Narratives
There are no narratives available yet.
Recent SEQUA News & Updates
No updates
Sequana Medical NV Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.76
- Gross Margin
- 74.94%
- Net Profit Margin
- -42,325.70%
- Debt/Equity Ratio
- -89.5%
Sequana Medical NV Competitors
About SEQUA
- Founded
- 2006
- Employees
- 48
- CEO
- WebsiteView website
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Belgian Market Performance
- 7 Days: -3.0%
- 3 Months: -0.2%
- 1 Year: 5.6%
- Year to Date: 4.9%
Over the last 7 days, the market has dropped 3.0%, driven by a pullback of 12% in the Consumer Staples sector. In contrast, the Healthcare sector has actually gained 7.5%. As for the longer term, the market has actually risen by 5.6% in the last year. Earnings are forecast to grow by 14% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading